These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 25500171)
1. [Prescription drug consumption recovery following the co-payment change: Evidence from a regional health service]. Sánchez DP; Guillén JJ; Torres AM; Arense JJ; López Á; Sánchez FI Aten Primaria; 2015; 47(7):411-8. PubMed ID: 25500171 [TBL] [Abstract][Full Text] [Related]
2. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436 [TBL] [Abstract][Full Text] [Related]
3. Does €1 Per Prescription Make a Difference? Impact of a Capped Low-Intensity Pharmaceutical Co-Payment. García-Gómez P; Mora T; Puig-Junoy J Appl Health Econ Health Policy; 2018 Jun; 16(3):407-414. PubMed ID: 29549661 [TBL] [Abstract][Full Text] [Related]
4. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671 [TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125 [TBL] [Abstract][Full Text] [Related]
6. The effect of a change in co-payment on prescription drug demand in a National Health System: The case of 15 drug families by price elasticity of demand. Hernández-Izquierdo C; González López-Valcárcel B; Morris S; Melnychuk M; Abásolo Alessón I PLoS One; 2019; 14(3):e0213403. PubMed ID: 30917142 [TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical policies: effects of restrictions on reimbursement. Green CJ; Maclure M; Fortin PM; Ramsay CR; Aaserud M; Bardal S Cochrane Database Syst Rev; 2010 Aug; 2010(8):CD008654. PubMed ID: 20687098 [TBL] [Abstract][Full Text] [Related]
8. The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan. Chen LC; Schafheutle EI; Noyce PR Res Social Adm Pharm; 2009 Sep; 5(3):211-24. PubMed ID: 19733822 [TBL] [Abstract][Full Text] [Related]
9. Paying for formerly free medicines in Spain after 1 year of co-payment: changes in the number of dispensed prescriptions. Puig-Junoy J; Rodríguez-Feijoó S; Lopez-Valcarcel BG Appl Health Econ Health Policy; 2014 Jun; 12(3):279-87. PubMed ID: 24696429 [TBL] [Abstract][Full Text] [Related]
10. The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis. Damiani G; Federico B; Anselmi A; Bianchi CB; Silvestrini G; Iodice L; Navarra P; Da Cas R; Raschetti R; Ricciardi W BMC Health Serv Res; 2014 Jan; 14():6. PubMed ID: 24393340 [TBL] [Abstract][Full Text] [Related]
11. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD Med Care; 2017 Feb; 55(2):191-198. PubMed ID: 27579915 [TBL] [Abstract][Full Text] [Related]
12. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0). Academy of Managed Care Pharmacy J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720 [TBL] [Abstract][Full Text] [Related]
13. Impact of cost sharing on prescription drugs used by Medicare beneficiaries. Goedken AM; Urmie JM; Farris KB; Doucette WR Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109 [TBL] [Abstract][Full Text] [Related]
14. The effect of a Medicaid drug copayment program on the utilization and cost of prescription services. Nelson AA; Reeder CE; Dickson WM Med Care; 1984 Aug; 22(8):724-36. PubMed ID: 6433121 [TBL] [Abstract][Full Text] [Related]
15. [Impact of the Pharmaceutical Copayment Reform on the Use of Antidiabetics, Antithrombotics and for Chronic Obstructive Airway Disease Agents, Spain]. Puig-Junoy J; Rodríguez-Feijóo S; González López-Valcárcel B; Gómez-Navarro V Rev Esp Salud Publica; 2016 Apr; 90():E6. PubMed ID: 27125567 [TBL] [Abstract][Full Text] [Related]
16. The international generalisability of evidence for health policy: A cross country comparison of medication adherence following policy change. Sinnott SJ; Whelton H; Franklin JM; Polinski JM Health Policy; 2017 Jan; 121(1):27-34. PubMed ID: 27916432 [TBL] [Abstract][Full Text] [Related]
17. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals. Andersson K; Bergström G; Petzold MG; Carlsten A Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449 [TBL] [Abstract][Full Text] [Related]
18. Prescription duration after drug copay changes in older people: methodological aspects. Schneeweiss S; Maclure M; Soumerai SB J Am Geriatr Soc; 2002 Mar; 50(3):521-5. PubMed ID: 11943050 [TBL] [Abstract][Full Text] [Related]
19. The Effect of Changes in Cost Sharing on the Consumption of Prescription and Over-the-Counter Medicines in Catalonia. Martínez-Jiménez M; García-Gómez P; Puig-Junoy J Int J Environ Res Public Health; 2021 Mar; 18(5):. PubMed ID: 33806543 [TBL] [Abstract][Full Text] [Related]
20. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea. Lee IH; Bloor K; Hewitt C; Maynard A Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]